Weekly Digest - May 2025

Weekly Digest - May 2025

07 May 2025: ENHERTU (Trastuzumab deruxtecan) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase 3 trial

  • In the DESTINY-Breast11 Phase 3 trial, Enhertu, followed by Trastuzumab and Pertuzumab (THP), significantly improved pathologic complete response (pCR) versus the standard regimen in high-risk, early-stage HER2-positive breast cancer
  • Event-free survival (EFS) data showed a positive trend favouring Enhertu, followed by THP, although the endpoint was not yet mature and will continue to be followed
  • Enhertu followed by THP showed an improved safety profile with no new concerns, and rates of interstitial lung disease were similar to ddAC-THP
  • Enhertu has now shown efficacy across six Phase 3 breast cancer trials and is being studied further in early and metastatic HER2-positive and HER2-low disease settings

For full story click  here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home